VB Spine to Acquire Exclusive Rights to xvision Spine System from Augmedics

Shots: VB Spine has entered into a definitive agreement with Augmedics to secure exclusive rights to the xvision Spine System, enhancing precision in open, minimally invasive, & percutaneous spine procedures through advanced augmented reality (AR) navigation tech Acquisition will expand VB Spine’s enhanced visualization portfolio by adding AR navigation capabilities, &, subject to regulatory approvals…

ByRidhi RastogiFebruary 17, 2026

Shionogi to Acquire Tanabe Pharma’s Radicava Franchise in $2.5B Rare Disease Deal

Shots: Shionogi to acquire a newly established company that will be created by Tanabe Pharma to hold the rights to Radicava ORS (edaravone) & IV Radicava As per the deal, Tanabe Pharma will establish a new entity, & Shionogi will acquire 100% of its shares, with Tanabe’s US Radicava business company becoming a wholly owned…

ByRidhi RastogiDecember 23, 2025

Akebia Therapeutics Acquires Q32 Bio’s Complement Inhibitor ADX-097 for ~$592M

Shots: Q32 Bio has sold ADX-097, a P-II complement inhibitor, to Akebia Therapeutics As per the deal, Akebia will acquire ADX-097 from Q32 Bio for ~$592M, incl. $12M in upfront & near-term milestones ($7M at signing, $3M after 6mos., $2M payable upon the earlier of a milestone or end-2026), plus development, regulatory & commercial milestones &…

ByRidhi RastogiDecember 2, 2025

VB Spine to Acquire Exclusive Rights to xvision Spine System from Augmedics

Shionogi to Acquire Tanabe Pharma’s Radicava Franchise in $2.5B Rare Disease Deal

Akebia Therapeutics Acquires Q32 Bio’s Complement Inhibitor ADX-097 for ~$592M

Contact US

FOLLOW US